Abiopharma

🔍 HAGEDORN JAMES (Director)

Company: SCOTTS MIRACLE-GRO CO (SMG)

Report Date: 2026-04-27

Detailed Transactions and Holdings:

• Acquired 37 shares of Common Shares at $54.67 per share (Direct)
  Date: 2026-03-31 | Code: J | equity_swap_involved: 0 | shares_owned_after: 88,591.57 | transaction_form_type: 5
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-04-27 | Code: H | nature_of_ownership: By 401(K) Plan | shares_owned_after: 31,533.64
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-04-27 | Code: H | nature_of_ownership: HPLP | shares_owned_after: 997,910.00 | Footnotes: F1
• Acquired 1,226 shares of Phantom Stock (Derivative)
  Date: 2026-04-27 | Code: A | equity_swap_involved: 0 | shares_owned_after: 239,899.40 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Pursuant to Exchange Act Rule 16a-1(a)(1), the reporting person may be deemed, solely for purposes of determining whether he is a beneficial owner of more than 10% of the common shares of the Issuer ("Common Shares"), to be the beneficial owner of the securities of the Issuer that are held by Hagedorn Partnership, L.P., a Delaware limited partnership in which the reporting person is a general partner (the "Partnership"). Represents the aggregate proportionate interest of the reporting person and those family members in whose holdings he may be deemed to have a pecuniary interest, in Common Shares held by the Partnership.
• F2: Each share of phantom stock represents the right to receive one common share of Issuer or the cash value thereof.
• F3: Shares of phantom stock are payable in cash following termination of the reporting person's employment with Issuer. The reporting person may transfer his/her phantom stock into an alternative investment at any time.